Glycemic control and the complications of diabetes: Afer the diabetes control and complications trial

S. M. Strowig, Philip Raskin

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations

Abstract

Although the discovery of insulin extended and improved the lives of individuals with insulin-dependent diabetes mellitus, it soon became clear that the long-term complications of diabetes would result in considerable morbidity and mortality. Before 1993, research suggested a relationship between glycemic control and diabetic complications. Data derived from experimental diabetes in animals indicated that controlling hyperglycemia could prevent the subsequent development of diabetic retinopathy and nephropathy. In humans, however, many of the data were collected retrospectively and before the availability of glycosylated hemoglobin measurements. Prospective clinical trials were relatively small and of short duration and consisted of patients with various characteristics. Not surprisingly, results were inconclusive. The Diabetes Control and Complications Trial, a 10-year prospective multicenter trial of >1,400 patients, convincingly demonstrated that intensive insulin therapy designed to achieve near-normoglycemia significantly reduced the risk for the development and progression of the microvascular complications of diabetes. Although intensive diabetes treatment requires a greater commitment of resources, the associated reduction in microvascular complications makes intensive therapy cost-effective over the long term. The health care system should support intensive diabetes treatment for appropriate diabetic patients.

Original languageEnglish (US)
Pages (from-to)237-257
Number of pages21
JournalDiabetes Reviews
Volume3
Issue number2
StatePublished - 1995

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Glycemic control and the complications of diabetes: Afer the diabetes control and complications trial'. Together they form a unique fingerprint.

Cite this